ORYZON Genomics
Contact details
Carrer Sant Ferran, 74 PO. Almeda
08940 CORNELLA DE LLOBREGAT (Barcelona)
Espanya
Telephone: +34 934 037 196
Fax: +34 934 034 792
info@oryzon.com
Visit Website
Contact person
Carlos Buesa Arjol, Director general | etorrell@oryzon.com
General information
Type of organization: Company
Founding year: 2000
Origin of the group: University
Number of locations worldwide: 1
Number of locations in Catalonia: 1
Business model and activity description
Description
ORYZON is the leading biomarker discovery company in Spain and has a complementary diagnostic and therapeutic pipeline focusing on oncology and neurodegenerative disorders. In 2008, the Company acquired Crystax Biopharmaceuticals, bolstering fragment screening, crystallographic and structural genomic expertise in the process. Oryzon’s biomarker programs have successfully resulted not only in the identification of a new molecular signature useful for the early diagnosis of endometrial cancer (which is now being validated in a clinical trial with 500 patients recruited from 16 hospitals), but also in the characterization of new druggable targets for several oncological and neurological diseases. It has a fast-moving, dynamic discovery team with more than 30 chemists and biologists focused on its three major small molecule programs. These first-in-class programs are expected to entre in Phase I in 2012. Oryzon is developing also therapeutic antibodies using Dyax technology. Finally, in addition to its own R&D programs, the Company is the leading provider in Spain of some fee for service capabilities, like X-ray crystallography services for structure-based drug design and fragment-based screening, and several genomics applications.
Main activities
- >> R&D
- >> Services & Related
Main areas
- >> Human Health: In Vitro Diagnosis
- >> Human Health: Pharmacological or Biological Therapeutics
- >> Contract Research Organisation (private entity) / Outsourced R&D (for research groups and public entities)
R&D lines
Molecular Diagnostics in CancerDrug discovery and development in New epigenetic targets in cancer and neurodegenerative disordersDevelopment of Therapeutic Human Monoclonal antibodies
Therapeutic areas
- >> Central Nervous System
- >> Oncology
Technologies
- >> Bioinformatics
- >> Biostatistics
- >> Cristalography
- >> In silico analysis
- >> Medicinal chemistry
- >> Peptides & proteins
- >> Omics
Differential features of the technology used, main facilities and/or instrumentations available
Our programs use a powerful combination of in-house state of the art of biomarker discovery, target validation, fragment screening and molecular modeling technologies, accompanied by traditional SAR approaches, to identify new chemical entities possessing novel mechanisms of action that have the potential to be first-in-class.
Last updated
04/05/2012